As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question
Executive Summary
FDA’s approval of Bristol-Myers Squibb’s Yervoy (ipilimumab) for unresectable or metastatic melanoma March 25 grabbed attention for several reasons – the monoclonal antibody is the first new treatment approved for advanced melanoma in 13 years and the first ever to demonstrate a survival benefit.
You may also be interested in...
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.
Bristol Tries Out New Selling Strategy With Yervoy Launch
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.